secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lipocine Inc. (LPCN)
CIK:        0001535955
Form:       8-K
Filed at:   2025-08-26T23:59:59+00:00
Accession:  0001493152-25-012325
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipocine announces LPCN 2101 abstracts accepted for AES 2025 annual meeting
---------------------------------------------------------------------------

- Two LPCN 2101 abstracts accepted for poster presentation at AES 2025 (Dec 5-9, Atlanta).
- Abstracts cover oral toxicokinetics and clinical pharmacokinetics/tolerability of LPCN 2101.
- LPCN 2101 is a GABA-A receptor modulating neuroactive steroid for potential treatment of epilepsy.
- Data remain embargoed until November 24, 2025, per AES policy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1535955/000149315225012325/0001493152-25-012325-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1535955/000149315225012325/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-012325

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer